Want to see BNTC full AI Analyst Report?
Top Page
Benitec Biopharma
(NASDAQ:BNTC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$13.00
▼(-7.67% Downside)
Action:Reiterated
Date:05/14/26
The score is driven primarily by weak financial performance (large losses and ongoing cash burn despite minimal revenue). Technicals add pressure with the stock trading below major moving averages and slightly negative MACD. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Low Financial Leverage
The company’s balance sheet shows minimal debt relative to sizable equity and assets, reducing refinancing and interest-rate risk. Conservatively leveraged capital structure preserves strategic optionality to fund R&D or pursue partnerships without immediate solvency pressure, a durable strength.
Negative Factors
Deep Operating Losses
Large, persistent operating and net losses consume equity and limit reinvestment capacity absent external capital or material revenue growth. Over months, this reduces flexibility to advance multiple programs simultaneously and increases dependency on milestone financing or dilutive raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
The company’s balance sheet shows minimal debt relative to sizable equity and assets, reducing refinancing and interest-rate risk. Conservatively leveraged capital structure preserves strategic optionality to fund R&D or pursue partnerships without immediate solvency pressure, a durable strength.
Read all positive factors
Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$454.16M
Dividend YieldN/A
Average Volume (3M)88.42K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth41.21%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.11
Shares Outstanding34,354,336
10 Day Avg. Volume101,418
30 Day Avg. Volume88,422
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-264.91
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$25.00Price Target Upside77.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$27.32M
Benitec Biopharma Business Overview & Revenue Model
Company Description
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring hu...
How the Company Makes Money
Benitec Biopharma’s business model is typical of an early-stage/pre-revenue biotechnology company: it invests primarily in research and development to advance ddRNAi-based drug candidates and seeks to generate future value by progressing these pro...
Benitec Biopharma Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 75.00K | 73.00K | 59.00K |
| Gross Profit | -475.00K | -396.00K | -343.00K | 75.00K | 64.00K | -64.00K |
| EBITDA | -53.46M | -41.37M | -22.15M | -18.70M | -17.78M | -13.45M |
| Net Income | -48.88M | -37.92M | -21.75M | -19.56M | -18.21M | -13.88M |
Balance Sheet | ||||||
| Total Assets | 187.00M | 99.59M | 52.21M | 4.46M | 5.97M | 21.38M |
| Cash, Cash Equivalents and Short-Term Investments | 184.76M | 97.74M | 50.87M | 2.48M | 4.06M | 19.77M |
| Total Debt | 876.00K | 849.00K | 284.00K | 559.00K | 811.00K | 213.00K |
| Total Liabilities | 3.67M | 2.30M | 4.96M | 4.26M | 3.09M | 1.37M |
| Stockholders Equity | 183.33M | 97.30M | 47.25M | 202.00K | 2.88M | 20.01M |
Cash Flow | ||||||
| Free Cash Flow | -20.59M | -23.61M | -19.58M | -18.01M | -15.91M | -13.05M |
| Operating Cash Flow | -20.57M | -23.59M | -19.40M | -18.01M | -15.90M | -12.83M |
| Investing Cash Flow | -27.51K | -18.00K | -179.00K | -1.00K | -13.00K | -221.00K |
| Financing Cash Flow | 106.87M | 70.48M | 68.03M | 16.02M | 0.00 | 22.52M |
Benitec Biopharma Technical Analysis
Positive
14.08
Price Trends
11.81
Positive
11.63
Positive
12.52
Positive
Market Momentum
0.46
Negative
59.81
Neutral
56.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Positive. The current price of 14.08 is above the 20-day moving average (MA) of 11.90, above the 50-day MA of 11.81, and above the 200-day MA of 12.52, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 59.81 is Neutral, neither overbought nor oversold. The STOCH value of 56.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTC.
Benitec Biopharma Risk Analysis
Benitec Biopharma disclosed 68 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Benitec Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $679.59M | -4.89 | -36.83% | ― | 383560.87% | 20.87% | |
52 Neutral | $365.80M | ― | -70.79% | ― | ― | 28.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $549.73M | -47.83 | -4.21% | ― | 121.11% | 80.74% | |
44 Neutral | $454.16M | -11.91 | -34.82% | ― | ― | 41.21% | |
44 Neutral | $18.95M | -1.27 | -64.17% | ― | -100.00% | 94.65% | |
43 Neutral | $800.60M | -4.37 | -78.12% | ― | ― | 7.21% |
* Healthcare Sector Average
BNTC
Benitec Biopharma
13.22
-0.27
-2.00%
TVRD
Tvardi Therapeutics
2.02
-19.50
-90.61%
ASMB
Assembly Biosciences
27.74
9.18
49.46%
RCKT
Rocket Pharmaceuticals
3.84
1.03
36.65%
FDMT
4D Molecular Therapeutics
13.00
9.05
229.11%
AURA
Aura Biosciences Inc
7.74
1.58
25.65%
Benitec Biopharma Corporate Events
Executive/Board Changes
Benitec Biopharma Announces Board Changes and New Director
Neutral
May 29, 2026
On May 22, 2026, Benitec Biopharma Inc.’s board appointed David Friedman as a Class III director, with a term running until the 2028 annual meeting of stockholders. In connection with his appointment, Friedman received options on May 26, 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.